Novo Nordisk

Big pharma heads towards important readouts
Big pharma heads towards important readouts
EP Vantage
Ozempic
Novo Nordisk
etrolizumab
Roche
Ipatasertib
finerenone
Bayer
filgotinib
Gilead Sciences
Galapagos
Avalglucosidase alfa
Sanofi
Rinvoq
AbbVie
clinical trials
Flag link:
Novo's diabetes drug also appears to work in NASH
Novo's diabetes drug also appears to work in NASH
BioPharma Dive
Novo Nordisk
NASH
semaglutide
Flag link:
Sidelined by COVID-19 pandemic, Team Novo Nordisk cyclists crank and jam on social media instead
Sidelined by COVID-19 pandemic, Team Novo Nordisk cyclists crank and jam on social media instead
Fierce Pharma
Novo Nordisk
pharma marketing
social media
Flag link:
The top pharma companies in social media
The top pharma companies in social media
Fierce Pharma
social media
Boehringer Ingelheim
AbbVie
GSK
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Flag link:
Genentech, Novo Nordisk and AbbVie top the list of best workplaces in biopharma
Genentech, Novo Nordisk and AbbVie top the list of best workplaces in biopharma
Fierce Pharma
Roche
Genentech
Novo Nordisk
AbbVie
Fortune
employees
Flag link:
Will Novo’s big thinking in obesity pay off?
Will Novo’s big thinking in obesity pay off?
EP Vantage
Novo Nordisk
obesity
Ozempic
AM833
clinical trials
Flag link:
Novo Nordisk expands 90-day free insulin program to workers affected by COVID-19
Novo Nordisk expands 90-day free insulin program to workers affected by COVID-19
Fierce Pharma
Novo Nordisk
insulin
diabetes
COVID-19
Flag link:
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Xconomy
Novo Nordisk
clinical trials
concizumab
hemophilia
Flag link:
Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs
Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs
Fierce Biotech
Novo Nordisk
Saxenda
obesity
food cravings
Flag link:
Novo bids for recognition in the year of NASH
Novo bids for recognition in the year of NASH
EP Vantage
NASH
Novo Nordisk
Ozempic
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
Fierce Biotech
diabetes
insulin
Mt Sinai
Novo Nordisk
Ozempic
Rybelsus
Victoza
Eli Lilly
Trulicity
AstraZeneca
Bydureon
Flag link:
Lilly, Novo Nordisk Fight Insulin Biosimilars With Tweaks to FDA Draft Guidance
Lilly, Novo Nordisk Fight Insulin Biosimilars With Tweaks to FDA Draft Guidance
RAPS.org
diabetes
insulin
biosimilars
Eli Lilly
Novo Nordisk
FDA
competition
Flag link:
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
BioSpace
earnings
Bristol-Myers Squibb
AbbVie
Novo Nordisk
Merck
GSK
Seattle Genetics
Flag link:
Novo Nordisk investing $117.4M in manufacturing site in Denmark
Novo Nordisk investing $117.4M in manufacturing site in Denmark
Fierce Pharma
Novo Nordisk
insulin
diabetes
drug manufacturing
Flag link:
Ozempic acceleration buoys Novo Nordisk, and threatens Lilly
Ozempic acceleration buoys Novo Nordisk, and threatens Lilly
Pharmaforum
Novo Nordisk
earnings
Ozempic
Eli Lilly
diabetes
Flag link:
NICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions
NICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions
Fierce Pharma
Novo Nordisk
Saxenda
UK
NICE
Flag link:
Novo Nordisk’s quiet entry into the year of Alzheimer’s
Novo Nordisk’s quiet entry into the year of Alzheimer’s
EP Vantage
Novo Nordisk
Victoza
Alzheimer's disease
Flag link:
Novo Nordisk's diabetes pill Rybelsus to be covered by Express Scripts
Novo Nordisk's diabetes pill Rybelsus to be covered by Express Scripts
Reuters
Novo Nordisk
Rybelsus
Express Scripts
PBMs
Flag link:
Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication
Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication
Endpoints
Novo Nordisk
Ozempic
diabetes
cardiovascular events
FDA
Flag link:

Pages